In conclusion, CIGB-258 treatment improved the structural stabilization of lipid-free apoA-I against the glycation stress of CML to maintain its antioxidant activity. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.